Cure­Vac seeks to ac­cel­er­ate vac­cine in­fringe­ment case against Pfiz­er and BioN­Tech

Cure­Vac is go­ing on the of­fen­sive against Pfiz­er and BioN­Tech, say­ing that it will seek to ac­cel­er­ate its lit­i­ga­tion around patents re­lat­ed to the man­u­fac­ture of the Covid-19 vac­cine Comir­naty.

The Ger­man biotech com­pa­ny an­nounced Fri­day that the case, which orig­i­nal­ly launched in the US last sum­mer, has been trans­ferred from the fed­er­al dis­trict court of Mass­a­chu­setts to the east­ern dis­trict court in Vir­ginia as part of an ef­fort to speed up the lit­i­ga­tion, po­ten­tial­ly al­low­ing for a tri­al as soon as next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER